Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3164 141 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Incyte markets the first JAK inhibitor approved for any use, Jakafi (ruxolitinib). Add an interesting pipeline, and INCY is fun to follow, if not own. Please contribute, and good luck!
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3164Well, regards the in-house combination, ...they are main sponsor and they let KeMiljenko Zuanic-January 23
3163downstream = wrong wordscaram(o)uche-January 9
3162You're not the only one who's talking about a PFE-BMY hookup :- )DewDiligence_on_SI-January 9
3161Indeed, P2 Epa-PD1 chombo data v PD1 mono (multiple indications) are very stronMiljenko Zuanic-January 9
3160These findings are important translationally, because they suggest broader cliniscaram(o)uche-January 9
3159>> At JPM, INCY was cautious on IDO1 << With all of the commentaryscaram(o)uche-January 9
3158At JPM, INCY was cautious on IDO1, so...PFE exiting IDO-target may (after hearinMiljenko Zuanic-January 9
3157Celgene buying fedratinib for what????? PGS and friends discussing it at twittescaram(o)uche-January 7
3156Thanks, we agree Indo is not an INDO-1 inhibitor. <Thus, indoximod acts as aMiljenko Zuanic-January 4
3155I don't really understand the PFE decision. Based on IDO's role, it'former_pgs1January 4
3154I do not think that it is kynurenine level (as biomarker) that describe path forMiljenko Zuanic-January 4
3153The main differentiating characteristic of the iTeos compound was its penetratiotuck1January 4
3152And there was good rationale to go after malignant brain tumor (probably not witMiljenko Zuanic-January 4
3151With related note, PFE/Roche are out: So, what is wrong with 1000mMiljenko Zuanic-January 4
3150IDO/PD1 . . . Here's is INCY's presentation, which dose give demotuck-9/9/2017
3149IDO/PD1 combo battle part 2: Here is the data for Epacadostat/Keytruda in melantuck-9/9/2017
3148Regards the INCY (and many others bio-comp) PGS knows much more than I do. BestMiljenko Zuanic-9/8/2017
3147Certainly is. Landscape changing fast. Which is a good thing, unless you'rscaram(o)uche-9/8/2017
3146It is also big push for GLPG/GILD! JAK1-3 and STAT are downstream of the IL4/13Miljenko Zuanic-9/7/2017
3145 Wow. <i>NORTH CHICAGO, Ill., Sept. 7, 2017 /PRNewswire/ scaram(o)uche-9/7/2017
3144Yup, results look comparable to IO/IO (20% CR) with +12m PFS. If results hold iMiljenko Zuanic-9/7/2017
3143Took awhile for that trade to pay, hope you didn't sell for that dinner monescaram(o)uche-9/7/2017
3142Updated Indoximod/Keytruda data: Updated Data for Indoximod Plus KEYTRUDA®tuck-9/7/2017
3141Epacadostat + Pembrolizumab at ESMO, drilling into the melanoma cohort now: >tuck-8/31/2017
3140<So, I get what MZ and AF are saying. Indoximod seems to work by by targetingMiljenko Zuanic-6/8/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.